Immutep Valuation Multiples

Immutep Overview

About Immutep

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3’s ability to stimulate the body’s immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Founded

1987

HQ

Employees

44

Website

immutep.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $16M

EBITDA: ($40M)

EV

$585K

Valuation Multiples

Multiples.vc

Start free trial

Immutep Financials

Immutep reported last 12-month revenue of $16M and negative EBITDA of ($40M).

In the same LTM period, Immutep generated $16M in gross profit, ($40M) in EBITDA losses, and had net loss of ($40M).

Immutep P&L

In the most recent fiscal year, Immutep reported revenue of $3M and EBITDA of ($42M).

Immutep expects next 12-month revenue of XXX and NTM EBITDA of XXX

Immutep Stock Performance

Immutep has current market cap of $70M, and enterprise value of $585K.

Immutep's stock price is $0.05.

Immutep Valuation Multiples

Immutep trades at 0.0x EV/Revenue multiple, and (0.0x) EV/EBITDA.

Immutep Financial Valuation Multiples

As of April 21, 2026, Immutep has market cap of $70M and EV of $585K.

Equity research analysts estimate Immutep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immutep has a P/E ratio of (1.8x).

Immutep Margins & Growth Rates

Immutep's revenue in the last 12 month declined by (63%).

Immutep's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.1M for the same period.

Immutep's rule of 40 is (353%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Immutep's rule of X is (331%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Immutep Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Immutep M&A Activity

Immutep acquired XXX companies to date.

Last acquisition by Immutep was on XXXXXXXX, XXXXX. Immutep acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Immutep Investment Activity

Immutep invested in XXX companies to date.

Immutep made its latest investment on XXXXXXXX, XXXXX. Immutep invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).